Literature DB >> 21263450

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Mark O Goodarzi1, Daniel A Dumesic, Gregorio Chazenbalk, Ricardo Azziz.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with a prevalence of up to 10%. Various diagnostic criteria have been proposed, generally centered around the features of hyperandrogenism and/or hyperandrogenemia, oligo-ovulation and polycystic ovarian morphology. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin production. Adipose tissue dysfunction has been implicated as a contributor to the insulin resistance observed in PCOS. Environmental and genetic factors also have a role in the development of PCOS. The syndrome is associated with numerous morbidities, including infertility, obstetrical complications, type 2 diabetes mellitus, cardiovascular disease, and mood and eating disorders. Despite these morbidities, PCOS may be common in our society owing to evolutionary advantages of the syndrome in ancient times, including smaller family sizes, reduced exposure to childbirth-related mortality, increased muscle mass and greater capacity to store energy. The diagnosis of PCOS hinges on establishing key features while ruling out other hyperandrogenic or oligo-ovulatory disorders. Treatment is focused on the goals of ameliorating hyperandrogenic symptoms, inducing ovulation and preventing cardiometabolic complications.
© 2011 Macmillan Publishers Limited. All rights reserved

Entities:  

Mesh:

Year:  2011        PMID: 21263450     DOI: 10.1038/nrendo.2010.217

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  221 in total

1.  Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls.

Authors:  Christopher R McCartney; Susan K Blank; Kathleen A Prendergast; Sandhya Chhabra; Christine A Eagleson; Kristin D Helm; Richard Yoo; R Jeffrey Chang; Carol M Foster; Sonia Caprio; John C Marshall
Journal:  J Clin Endocrinol Metab       Date:  2006-11-21       Impact factor: 5.958

2.  Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis.

Authors:  Jennifer R Wood; Daniel A Dumesic; David H Abbott; Jerome F Strauss
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

3.  A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.

Authors:  E M E W Heijnen; M J C Eijkemans; E G Hughes; J S E Laven; N S Macklon; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2005-08-25       Impact factor: 15.610

Review 4.  Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective.

Authors:  Sam Virtue; Antonio Vidal-Puig
Journal:  Biochim Biophys Acta       Date:  2010-01-06

5.  Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction.

Authors:  Toru Takeuchi; Osamu Tsutsumi; Yumiko Ikezuki; Yasushi Takai; Yuji Taketani
Journal:  Endocr J       Date:  2004-04       Impact factor: 2.349

6.  Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries.

Authors:  R Kaushal; N Parchure; G Bano; J-C Kaski; S S Nussey
Journal:  Clin Endocrinol (Oxf)       Date:  2004-03       Impact factor: 3.478

7.  Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

Authors:  Dorte Glintborg; Kurt Højlund; Nicoline R Andersen; Bo Falck Hansen; Henning Beck-Nielsen; Jørgen F P Wojtaszewski
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

8.  South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts.

Authors:  M Palep-Singh; H M Picton; K Vrotsou; D Maruthini; A H Balen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-03-26       Impact factor: 2.435

9.  Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.

Authors:  L Ibáñez; N Potau; I Francois; F de Zegher
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance.

Authors:  Paloma Alonso-Magdalena; Sumiko Morimoto; Cristina Ripoll; Esther Fuentes; Angel Nadal
Journal:  Environ Health Perspect       Date:  2006-01       Impact factor: 9.031

View more
  329 in total

1.  Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility.

Authors:  Michelle R Jones; Gregorio Chazenbalk; Ning Xu; Angela K Chua; Tamar Eigler; Emebet Mengesha; Yen-Hao Chen; Jung-Min Lee; Marita Pall; Xiaohui Li; Yii-Der I Chen; Kent D Taylor; Ruchi Mathur; Ronald M Krauss; Jerome I Rotter; Richard S Legro; Ricardo Azziz; Mark O Goodarzi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

2.  Epigenetic regulation of traf2- and Nck-interacting kinase (TNIK) in polycystic ovary syndrome.

Authors:  Da Li; Jiao Jiao; Yi-Ming Zhou; Xiu-Xia Wang
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

3.  Genetic variations in SREBP-1 and LXRα are not directly associated to PCOS but contribute to the physiological specifics of the syndrome.

Authors:  Birgit Knebel; Onno E Janssen; Susanne Hahn; Sylvia Jacob; Ulrike Nitzgen; Jutta Haas; Dirk Muller-Wieland; Jorg Kotzka
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

4.  Prevalence of polycystic ovary syndrome in adolescents.

Authors:  Shawna B Christensen; Mary Helen Black; Ning Smith; Mayra M Martinez; Steve J Jacobsen; Amy H Porter; Corinna Koebnick
Journal:  Fertil Steril       Date:  2013-06-05       Impact factor: 7.329

5.  Endometrial progesterone receptor isoforms in women with polycystic ovary syndrome.

Authors:  Min Hu; Juan Li; Yuehui Zhang; Xin Li; Mats Brännström; Linus R Shao; Håkan Billig
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

6.  Brown adipose tissue transplantation ameliorates polycystic ovary syndrome.

Authors:  Xiaoxue Yuan; Tao Hu; Han Zhao; Yuanyuan Huang; Rongcai Ye; Jun Lin; Chuanhai Zhang; Hanlin Zhang; Gang Wei; Huiqiao Zhou; Meng Dong; Jun Zhao; Haibin Wang; Qingsong Liu; Hyuek Jong Lee; Wanzhu Jin; Zi-Jiang Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-22       Impact factor: 11.205

7.  Association of PON1 gene polymorphisms with polycystic ovarian syndrome risk: a meta-analysis of case-control studies.

Authors:  D Liao; H Yu; L Han; C Zhong; X Ran; D Wang; L Mo
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

8.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

9.  Rapid and easy assessment of insulin resistance contributes to early detection of polycystic ovary syndrome.

Authors:  M Rizzo; E K Tyndall; S Frontoni; F Jacoangeli; F Sarlo; F Panebianco; A Mistorni; L Di Renzo; R Calafiore; G Luca; A De Lorenzo
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

10.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.